Pain Management

Atogepant was associated with fewer monthly migraine days, fewer acute medication use days, and greater QoL compared with rimegepant after 12 weeks.

A new study compared opioid utilization trajectories of patients initiating tramadol, hydrocodone, and oxycodone. Key takeaways at-a-glance, here.

Your daily dose of the clinical news you may have missed.

Oral VX-548 has the potential to fill the gap between drugs that are tolerable but lack efficacy and opioids with therapeutic efficacy but known risks, according to Vertex.

Your daily dose of the clinical news you may have missed.

Gabapentinoid use increased from 4.0% of the population reporting use of the medication in 2015 to 4.7% in 2021, according to new data.

In persons with COPD, use of the anticonvulsants was linked to a 39% increase in risk of severe disease exacerbation requiring hospital admission, study authors reported.

A recent review analyzed the effectiveness of nonpharmacologic therapies for neuropathic pain in older adults. Results in our new slide show.

Knee pain is the presenting symptom for ~5% of primary care visits. Following are highlight of a JAMA review covering the 3 most common etiologies.

Your daily dose of the clinical news you may have missed.

Among study participants with migraine, investigators observed consistent and persistent device efficacy for pain relief, pain freedom, and functional disability freedom.

Ubrogepant 100 mg taken during the migraine prodrome significantly reduced onset of moderate or severe headache for 24 hours after study-drug dose.

Cluster headache is rare and can be disabling. It can be misdiagnosed, particularly as migraine, but treatments are very different. Learn more in a short slide show.

Your daily dose of the clinical news you may have missed.

Only about 30% of more than 3000 adults surveyed in new poll reported talking to their clinician about the adverse effects OTC pain medications can have on blood pressure.

The goal of a PM&R physician is to identify the source of function-limiting pain and then develop the best plan for each patient to return them to their lives.

A recent study of patients with chronic low back pain sheds light on the association between sleep and opioid use on pain severity and interference.

His relationship with primary care physicians is one of the most important, says physiatrist DJ Kennedy, MD, and he lists the reasons in this interview.

RiVive™ nasal spray is the second nonprescription naloxone product approved by the FDA for the emergency treatment of opioid overdose.

Physiatrist DJ Kennedy, MD, is excited by the potential for new, and even existing technology, to present novel options for diagnosis, monitoring, and treatment.

A daily dose of clinical news on Patient Care you may have missed.

When is a primary care patient with back pain ready for referral to PM&R? No formulas available but basic principles hold true and earlier is always better.

The challenge posed by a complaint of back pain is not that the origin is unknowable but rather the remarkable heterogeneity in this condition, says the president-elect of the American Academy of Physical Medicine & Rehabilitation.

Your daily dose of clinical news you may have missed.

Results showed that the use of opioid analgesics did not confer any benefits for adults with acute low back pain or neck pain compared to placebo.

Is there evidence to support hypnosis for pediatric pain? A new review examined available studies to find out.

Your daily dose of clinical news you may have missed.

Brixadi is the first and only long-acting buprenorphine injectable that is available in both weekly and monthly doses.

A recent CDC report showed that approximately 20% of Americans experienced chronic pain in 2021 and certain groups were most vulnerable. Details in our new slideshow.

Your daily dose of clinical news you may have missed.